|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Ms E Walmsley
|
|
|
b)
|
Position/status
|
Chief Executive Officer
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 8 October 2020
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£14.2540
|
891
|
||
|
£14.2540
|
887
|
||
|
£14.2540
|
714
|
||
|
d)
|
Aggregated
information
|
2,492
|
|
|
Aggregated
volume Price
|
£14.2540
|
||
|
e)
|
Date
of the transaction
|
2020-10-12
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Dr H Barron
|
|
|
b)
|
Position/status
|
Chief Scientific Officer and President, R&D
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in ADSs following the re-investment
of dividends paid to shareholders on 8 October 2020 on ADSs held in
the Company's Deferred Annual Bonus Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
$37.1600
|
521
|
||
|
$37.1600
|
409
|
||
|
d)
|
Aggregated
information
|
930
|
|
|
Aggregated
volume Price
|
$37.1600
|
||
|
e)
|
Date
of the transaction
|
2020-10-12
|
|
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr R Connor
|
|
|
b)
|
Position/status
|
President, Global Vaccines
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 8 October 2020
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£14.2540
|
225
|
||
|
£14.2540
|
232
|
||
|
£14.2540
|
188
|
||
|
d)
|
Aggregated
information
|
645
|
|
|
Aggregated
volume Price
|
£14.2540
|
||
|
e)
|
Date
of the transaction
|
2020-10-12
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Ms D Conrad
|
|
|
b)
|
Position/status
|
SVP Human Resources
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 8 October 2020
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£14.2540
|
92
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
|
Aggregated
volume Price
|
|
||
|
e)
|
Date
of the transaction
|
2020-10-12
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr J Ford
|
|
|
b)
|
Position/status
|
Senior Vice President and General Counsel
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 8 October 2020
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£14.2540
|
132
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
|
Aggregated
volume Price
|
|
||
|
e)
|
Date
of the transaction
|
2020-10-12
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr J Ford
|
|
|
b)
|
Position/status
|
Senior Vice President and General Counsel
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in ADSs following the re-investment
of dividends paid to shareholders on 8 October 2020 on ADSs held in
the Company's Deferred Annual Bonus Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
$37.1600
|
44
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
|
Aggregated
volume Price
|
|
||
|
e)
|
Date
of the transaction
|
2020-10-12
|
|
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr N Hirons
|
|
|
b)
|
Position/status
|
SVP, Global Ethics & Compliance
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 8 October 2020
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£14.2540
|
99
|
||
|
£14.2540
|
97
|
||
|
£14.2540
|
70
|
||
|
d)
|
Aggregated
information
|
266
|
|
|
Aggregated
volume Price
|
£14.2540
|
||
|
e)
|
Date
of the transaction
|
2020-10-12
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Ms S Jackson
|
|
|
b)
|
Position/status
|
SVP, Global Communications & CEO Office
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 8 October 2020
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£14.2540
|
56
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
|
Aggregated
volume Price
|
|
||
|
e)
|
Date
of the transaction
|
2020-10-12
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr I Mackay
|
|
|
b)
|
Position/status
|
Chief Financial Officer
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 8 October 2020
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£14.2540
|
482
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
|
Aggregated
volume Price
|
|
||
|
e)
|
Date
of the transaction
|
2020-10-12
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr B McNamara
|
|
|
b)
|
Position/status
|
CEO, GSK Consumer Healthcare
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in ADSs following the re-investment
of dividends paid to shareholders on 8 October 2020 on ADSs held in
the Company's Deferred Annual Bonus Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
$37.1600
|
87
|
||
|
$37.1600
|
93
|
||
|
$37.1600
|
75
|
||
|
d)
|
Aggregated
information
|
255
|
|
|
Aggregated
volume Price
|
$37.1600
|
||
|
e)
|
Date
of the transaction
|
2020-10-12
|
|
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr L Miels
|
|
|
b)
|
Position/status
|
President, Global Pharmaceuticals
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 8 October 2020
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£14.2540
|
179
|
||
|
£14.2540
|
216
|
||
|
£14.2540
|
247
|
||
|
d)
|
Aggregated
information
|
642
|
|
|
Aggregated
volume Price
|
£14.2540
|
||
|
e)
|
Date
of the transaction
|
2020-10-12
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr D Redfern
|
|
|
b)
|
Position/status
|
Chief Strategy Officer
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 8 October 2020
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£14.2540
|
183
|
||
|
£14.2540
|
220
|
||
|
£14.2540
|
158
|
||
|
d)
|
Aggregated
information
|
561
|
|
|
Aggregated
volume Price
|
£14.2540
|
||
|
e)
|
Date
of the transaction
|
2020-10-12
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr R Simard
|
|
|
b)
|
Position/status
|
President, Pharmaceuticals Supply Chain
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 8 October 2020
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£14.2540
|
79
|
||
|
£14.2540
|
112
|
||
|
d)
|
Aggregated
information
|
191
|
|
|
Aggregated
volume Price
|
£14.2540
|
||
|
e)
|
Date
of the transaction
|
2020-10-12
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Ms K Terrell
|
|
|
b)
|
Position/status
|
Chief Digital & Technology Officer
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in ADSs following the re-investment
of dividends paid to shareholders on 8 October 2020 on ADSs held in
the Company's Deferred Annual Bonus Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
$37.1600
|
31
|
||
|
$37.1600
|
110
|
||
|
$37.1600
|
76
|
||
|
d)
|
Aggregated
information
|
217
|
|
|
Aggregated
volume Price
|
$37.1600
|
||
|
e)
|
Date
of the transaction
|
2020-10-12
|
|
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr P Thomson
|
|
|
b)
|
Position/status
|
President, Global Affairs
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 8 October 2020
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£14.2540
|
124
|
||
|
£14.2540
|
128
|
||
|
£14.2540
|
91
|
||
|
d)
|
Aggregated
information
|
343
|
|
|
Aggregated
volume Price
|
£14.2540
|
||
|
e)
|
Date
of the transaction
|
2020-10-12
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: October
14, 2020
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|